Vertex Pharmaceuticals Incorporated
VRTXNASDAQHealthcare● Active
$442.96
$-3.87(-0.87%)
Market Cap$112.4B
P/E Ratio—
52W High$507.92
52W Low$362.5
Vertex Pharmaceuticals Incorporated (VRTX) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · VRTX · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $3.95B | ($0.54B) | $3.62B | $3.32B | $2.34B |
| Depreciation & Amort. | $0.21B | $0.21B | $0.18B | $0.15B | $0.13B |
| Stock-Based Comp. | $0.00B | $0.70B | $0.58B | $0.49B | $0.44B |
| Change in Working Capital | ($1.20B) | ($0.51B) | ($0.27B) | $0.34B | ($0.11B) |
| Net Cash from Operations | $3.63B | ($0.49B) | $3.54B | $4.13B | $2.64B |
| Investing Activities | |||||
| Capital Expenditure | ($0.44B) | ($0.30B) | ($0.26B) | ($0.20B) | ($0.23B) |
| Purchases of Investments | ($6.40B) | ($7.70B) | ($3.79B) | ($0.69B) | ($0.61B) |
| Sales of Investments | $5.91B | $4.47B | $0.93B | $0.92B | $0.50B |
| Net Cash from Investing | ($0.95B) | ($3.77B) | ($3.14B) | ($0.32B) | ($0.34B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($2.02B) | ($1.18B) | ($0.43B) | $0.00B | ($1.43B) |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | ($0.01B) | ($0.03B) | ($0.04B) | ($0.09B) | ($0.02B) |
| Net Cash from Financing | ($2.26B) | ($1.49B) | ($0.56B) | ($0.07B) | ($1.48B) |
| Free Cash Flow | |||||
| Free Cash Flow | $3.19B | ($0.79B) | $3.28B | $3.93B | $2.41B |
| FCF Margin %(computed) | 26.45% | -7.17% | 33.22% | 43.95% | 31.80% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Vertex Pharmaceuticals Incorporated data
About Vertex Pharmaceuticals Incorporated (VRTX) Cash Flow Statement
Vertex Pharmaceuticals Incorporated generated operating cash flow of $3.63B and free cash flow of $3.19B for 2025 — a FCF margin of 26.45%. Capital expenditure was ($0.44B).
Frequently asked questions
VRTX · 4 questionsVertex Pharmaceuticals Incorporated generated free cash flow of $3.19B for 2025, up 504.1% year-over-year.
VRTX free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10